In this two-part series, In Vivo will explore why organ on chip technology exists, the factors driving and limiting their application in drug development, and how companies can benefit from using them.
The cost of developing and taking a new drug to market can range from a hair under a billion to almost $3bn, with a study from the London School of Economics giving an average of $1.3bn.
It also takes typically between 10 and 15 years. Imjudo (tremelimumab-actl) for example, was approved in October 2022 after nearly...
Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.
